Disorders of Hemostasis Associated with Chronic Kidney Disease

ABSTRACT

Chronic kidney disease (CKD) is a growing global health problem. CKD is typically associated with a prothrombotic tendency in the early stages of the disease, whereas in its more advanced stage, that is, end-stage renal disease, patients suffer from a prothrombotic tendency and, in many cases, a bleeding diathesis. The exact etiology behind the coexistence of these conflicting hemostatic disorders is poorly understood. This review critically appraises studies examining the abnormalities in the hemostasis pathway in patients with CKD, as well as the therapeutic options that are currently available to treat these individuals.

KEYWORDS

Chronic kidney disease - thrombosis - bleeding - hemostatic disorders

REFERENCES

• 1 Furie B, Furie B C. Mechanisms of thrombus formation.  N Engl J Med. 2008;  359(9) 938-949
• 2 Lane D A, Philippou H, Huntington J A. Directing thrombin.  Blood. 2005;  106(8) 2605-2612
• 3 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure.  Semin Thromb Hemost. 2004;  30(5) 579-589
• 4 Watson S, Berlanga O, Best D, Frampton J. Update on collagen receptor interactions in platelets: is the two-state model still valid?.  Platelets. 2000;  11(5) 252-258
• 5 Holtkötter O, Nieswandt B, Smyth N et al.. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen.  J Biol Chem. 2002;  277(13) 10789-10794
• 6 Bhagwat S S, Hamann P R, Still W C, Bunting S, Fitzpatrick F A. Synthesis and structure of the platelet aggregation factor thromboxane A2.  Nature. 1985;  315(6019) 511-513
• 7 Savage B, Shattil S J, Ruggeri Z M. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor.  J Biol Chem. 1992;  267(16) 11300-11306
• 8 Raines E W. PDGF and cardiovascular disease.  Cytokine Growth Factor Rev. 2004;  15(4) 237-254
• 9 Perry D J. Antithrombin and its inherited deficiencies.  Blood Rev. 1994;  8(1) 37-55
• 10 Fulcher C A, Gardiner J E, Griffin J H, Zimmerman T S. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.  Blood. 1984;  63(2) 486-489
• 11 Grosser T, Fries S, FitzGerald G A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.  J Clin Invest. 2006;  116(1) 4-15
• 12 Moncada S, Higgs A. The L-arginine-nitric oxide pathway.  N Engl J Med. 1993;  329(27) 2002-2012
• 13 Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis.  Thromb Haemost. 2003;  89(4) 610-621
• 14 Levey A S, Atkins R, Coresh J et al.. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes.  Kidney Int. 2007;  72(3) 247-259
• 15 Whaley-Connell A T, Sowers J R, Stevens L A Kidney Early Evaluation Program Investigators et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004.  Am J Kidney Dis. 2008;  51(4, suppl 2) S13-S20
• 16 Thijs A, Nanayakkara P W, Ter Wee P M, Huijgens P C, van Guldener C, Stehouwer C D. Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study.  Clin Nephrol. 2008;  70(4) 325-331
• 17 Hrafnkelsdóttir T, Ottosson P, Gudnason T, Samuelsson O, Jern S. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension.  Hypertension. 2004;  44(3) 300-304
• 18 Cantin B, Després J P, Lamarche B et al.. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study).  Am J Cardiol. 2002;  89(6) 662-666
• 19 Stec J J, Silbershatz H, Tofler G H et al.. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population.  Circulation. 2000;  102(14) 1634-1638
• 20 de la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature.  J Fam Pract. 1994;  39(5) 468-477
• 21 Shlipak M G, Fried L F, Crump C et al.. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency.  Circulation. 2003;  107(1) 87-92
• 22 Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease.  Atherosclerosis. 1998;  137(1) 133-139
• 23 Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment.  Blood Coagul Fibrinolysis. 2009;  , June 1 (Epub ahead of print)
• 24 Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation.  Clin Nephrol. 2006;  65(2) 97-102
• 25 Chu A J. Tissue factor mediates inflammation.  Arch Biochem Biophys. 2005;  440(2) 123-132
• 26 Tay K H, Lip G Y. What “drives” the link between the renin-angiotensin-aldosterone system and the prothrombotic state in hypertension?.  Am J Hypertens. 2008;  21(12) 1278-1279
• 27 Lindholm L H, Ibsen H, Dahlöf B LIFE Study Group et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359(9311) 1004-1010
• 28 Lewis E J, Hunsicker L G, Bain R P, Rohde R D. The Collaborative Study Group . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.  N Engl J Med. 1993;  329(20) 1456-1462
• 29 Brenner B M, Cooper M E, de Zeeuw D RENAAL Study Investigators et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.  N Engl J Med. 2001;  345(12) 861-869
• 30 Sechi L A, Novello M, Colussi G et al.. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage.  Am J Hypertens. 2008;  21(12) 1347-1353
• 31 Astrup A S, Tarnow L, Pietraszek L et al.. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.  Diabetes Care. 2008;  31(6) 1170-1176
• 32 Huang Y, Noble N A. PAI-1 as a target in kidney disease.  Curr Drug Targets. 2007;  8(9) 1007-1015
• 33 Segarra A, Chacón P, Martinez-Eyarre C et al.. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.  J Am Soc Nephrol. 2001;  12(6) 1255-1263
• 34 Małyszko J, Małyszko J S, Myśliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis.  Kidney Blood Press Res. 2004;  27(2) 71-77
• 35 Matsuo T, Koide M, Kario K, Suzuki S, Matsuo M. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure.  Haemostasis. 1997;  27(4) 163-167
• 36 Takagi M, Wada H, Mukai K et al.. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis.  Clin Appl Thromb Hemost. 1999;  5(2) 113-116
• 37 Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment.  Thromb Res. 1991;  64(1) 81-90
• 38 Gawaz M P, Dobos G, Späth M, Schollmeyer P, Gurland H J, Mujais S K. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.  J Am Soc Nephrol. 1994;  5(1) 36-46
• 39 Pawlak D, Malyszko J, Malyszko J S, Pawlak K, Buczko W, Mysliwiec M. Peripheral serotonergic system in uremia.  Thromb Res. 1996;  83(2) 189-194
• 40 Di Minno G, Cerbone A, Usberti M et al.. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen.  J Lab Clin Med. 1986;  108(3) 246-252
• 41 Noris M, Benigni A, Boccardo P et al.. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension.  Kidney Int. 1993;  44(2) 445-450
• 42 Hedges S J, Dehoney S B, Hooper J S, Amanzadeh J, Busti A J. Evidence-based treatment recommendations for uremic bleeding.  Nat Clin Pract Nephrol. 2007;  3(3) 138-153
• 43 Sabovic M, Salobir B, Preloznik Zupan I, Bratina P, Bojec V, Buturovic Ponikvar J. The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis.  Pathophysiol Haemost Thromb. 2005;  34(6) 274-278
• 44 Wasse H, Gillen D L, Ball A M et al.. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients.  Kidney Int. 2003;  64(4) 1455-1461
• 45 Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis.  Am J Kidney Dis. 1998;  31(6) 991-996
• 46 Zupan I P, Sabovic M, Salobir B, Ponikvar J B, Cernelc P. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients.  Am J Kidney Dis. 2003;  42(4) 746-751
• 47 Kidney Disease Outcomes Quality Initiative .NKF-KDOQI guidelines. http://Available at: www.kidney.org/professionals/kdoqi/guidelines.cfm Accessed January 18, 2010
• 48 Charytan D, Kuntz R E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease.  Kidney Int. 2006;  70(11) 2021-2030
• 49 Holden R M, Harman G J, Wang M, Holland D, Day A G. Major bleeding in hemodialysis patients.  Clin J Am Soc Nephrol. 2008;  3(1) 105-110
• 50 Ludwig S, Dharmalingam S, Erickson-Nesmith S et al.. Impact of simvastatin on hemostatic and fibrinolytic regulators in type 2 diabetes mellitus.  Diabetes Res Clin Pract. 2005;  70(2) 110-118
• 51 Fellström B C, Jardine A G, Schmieder R E AURORA Study Group et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.  N Engl J Med. 2009;  360(14) 1395-1407
• 52 Viganò G, Benigni A, Mendogni D, Mingardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding.  Am J Kidney Dis. 1991;  18(1) 44-49
• 53 Mannucci P M, Remuzzi G, Pusineri F et al.. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.  N Engl J Med. 1983;  308(1) 8-12
• 54 Livio M, Mannucci P M, Viganò G et al.. Conjugated estrogens for the management of bleeding associated with renal failure.  N Engl J Med. 1986;  315(12) 731-735